TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29504483

Group type: EXPERIMENTAL
Intervention: sTMS (four pulses twice daily)
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: sTMS
Number of subjects: 263
Study: 29505098

Group type: EXPERIMENTAL
Intervention: VEMOFIT (emotion-focused educational programme)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Attention control programme (active listening, social support)
Number of subjects: 124
Study: 29505137

Group type: EXPERIMENTAL
Intervention: Patients' perception of malnutrition
Number of subjects: 2197

Group type: EXPERIMENTAL
Intervention: Relatives' perception of malnutrition
Number of subjects: 2197

Group type: EXPERIMENTAL
Intervention: Physicians' perception of malnutrition
Number of subjects: 2197

Group type: EXPERIMENTAL
Intervention: Overall prevalence of malnutrition
Number of subjects: 2197
Study: 29505450

Group type: EXPERIMENTAL
Intervention: Customized device for measuring VO2
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Customized device for measuring VCO2
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Customized device for measuring EE
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Customized device
Number of subjects: 14
Study: 29505600

Group type: EXPERIMENTAL
Intervention: A20 upregulation during treated HIV disease
Number of subjects: 0
Study: 29505699

Group type: EXPERIMENTAL
Intervention: IMADETECT™ diagnostic test for patient inclusion and personalized target selection
Number of subjects: 0
Study: 29505795

Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention (one face-to-face session and two phone sessions delivered by a nurse)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 102
Study: 29506157

Group type: EXPERIMENTAL
Intervention: Isoglycemic intravenous glucose infusion (IIGI)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Oral glucose tolerance test (OGTT)
Number of subjects: 4
Study: 29506392

Group type: EXPERIMENTAL
Intervention: Ensartinib (X-396)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Crizotinib
Number of subjects: 0
Study: 29506478

Group type: EXPERIMENTAL
Intervention: S-1 and oxaliplatin (SOX)
Number of subjects: 36
Study: 29506503

Group type: EXPERIMENTAL
Intervention: Serum klotho levels
Number of subjects: 2101

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 2101
Study: 29506523

Group type: EXPERIMENTAL
Intervention: RAAS inhibition treatment
Number of subjects: 94
Study: 29506579

Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygen (HFNO) therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard oxygen therapy
Number of subjects: 0
Study: 29506984

Group type: EXPERIMENTAL
Intervention: LDL-C <70 mg/dL
Number of subjects: 2518

Group type: EXPERIMENTAL
Intervention: LDL-C <100 mg/dL
Number of subjects: 2518

Group type: EXPERIMENTAL
Intervention: Non-HDL-C targets
Number of subjects: 2518

Group type: EXPERIMENTAL
Intervention: ApoB targets
Number of subjects: 2518
Study: 29506988

Group type: EXPERIMENTAL
Intervention: Duligotuzumab (MEHD7945A)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cetuximab in combination with FOLFIRI
Number of subjects: 0
Study: 29507062

Group type: EXPERIMENTAL
Intervention: Piperacillin 4 g every 8 h
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Piperacillin
Number of subjects: 22
Study: 29507070

Group type: EXPERIMENTAL
Intervention: Intravenous ganciclovir therapy; specific dosage and duration not mentioned.
Number of subjects: 0
Study: 29507077

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin with cyclophosphamide, doxorubicin, and prednisone (BV+CHP; 6 cycles, then up to 10 cycles of brentuximab vedotin monotherapy)
Number of subjects: 26
Study: 29507099

Group type: EXPERIMENTAL
Intervention: 24-hour urinary sodium excretion (118.7 mmol)
Number of subjects: 4680

Group type: EXPERIMENTAL
Intervention: Potassium intake
Number of subjects: 4680

Group type: EXPERIMENTAL
Intervention: Dietary sodium
Number of subjects: 4680
Study: 29507706

Group type: EXPERIMENTAL
Intervention: Personalized supervised exercise program (DAPS)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Standard intervention (gym-membership with limited instructions and general dietary advice)
Number of subjects: 36
Study: 29507732

Group type: EXPERIMENTAL
Intervention: Occupational multicomponent rehabilitation including physical exercise and cognitive behavioral therapy (ACT) for either 8 or 17 full days.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Occupational multicomponent rehabilitation including physical exercise and ACT
Number of subjects: 30
Study: 29507971

Group type: EXPERIMENTAL
Intervention: Grazoprevir (GZR), 100 mg, and Elbasvir (EBR), 50 mg, immediately before transplantation; continued GZR-EBR for 12 weeks after transplantation for genotype 1 infection, and added Sofosbuvir, 400 mg, for genotype 2 or 3 infection for 12 weeks of triple therapy.
Number of subjects: 10
Study: 29508095

Group type: EXPERIMENTAL
Intervention: Ramucirumab 8 mg/kg every 2 weeks
Number of subjects: 36
Study: 29508268

Group type: EXPERIMENTAL
Intervention: Probiotics (Saccharomyces boulardii, Bifidobacterium lactis, Lactobacillus acidophilus, Lactobacillus plantarum)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (IBS without SIBO)
Number of subjects: 26
Study: 29509034

Group type: EXPERIMENTAL
Intervention: Adipose graft transposition procedure (AGTP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AGTP
Number of subjects: 0
Study: 29509546

Group type: EXPERIMENTAL
Intervention: PARP-1 PET imaging agent
Number of subjects: 0
Study: 29509764

Group type: EXPERIMENTAL
Intervention: High multimorbidity class (concomitant heart failure, peripheral vascular disease, and hypertension)
Number of subjects: 693388

Group type: EXPERIMENTAL
Intervention: Medium multimorbidity class (peripheral vascular disease and hypertension)
Number of subjects: 693388

Group type: COMPARATOR
Intervention: Low multimorbidity class
Number of subjects: 693388

Group type: EXPERIMENTAL
Intervention: Pharmacological therapies (aspirin, β-blockers, statins)
Number of subjects: 693388
Study: 29509992

Group type: EXPERIMENTAL
Intervention: Eplerenone (25 mg daily for 1 week followed by 50 mg daily for 23 weeks)
Number of subjects: 5
Study: 29510707

Group type: EXPERIMENTAL
Intervention: Watching television
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Using a computer
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Reading
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Socializing
Number of subjects: 173
Study: 29510709

Group type: EXPERIMENTAL
Intervention: 10 different non-wear criteria (≥ 10, 20, 30, 45, 60, and 90 min of consecutive zero counts without interruptions; ≥60 and 90 min with allowance for 1 and 2 min interruptions)
Number of subjects: 891

Group type: EXPERIMENTAL
Intervention: Log of non-wear periods
Number of subjects: 891

Group type: EXPERIMENTAL
Intervention: Non-wear criteria
Number of subjects: 891

Group type: EXPERIMENTAL
Intervention: Suggested non-wear criterion
Number of subjects: 891
Study: 29510735

Group type: EXPERIMENTAL
Intervention: Single 2-h pain catastrophizing class
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Pain-CBT (eight weekly 2-h group sessions with home exercises and readings)
Number of subjects: 231

Group type: COMPARATOR
Intervention: Single 2-h back pain health education class
Number of subjects: 231
Study: 29510739

Group type: EXPERIMENTAL
Intervention: Durvalumab therapy
Number of subjects: 9
Study: 29510755

Group type: EXPERIMENTAL
Intervention: Whole exome sequencing (WES) methodology using Illumina HiSEQ 2500
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Whole exome sequencing (WES) methodology
Number of subjects: 3
Study: 29510972

Group type: EXPERIMENTAL
Intervention: Adapted Wii Fit Balance Board
Number of subjects: 0

Group type: COMPARATOR
Intervention: OTS Wii Fit Balance Board
Number of subjects: 0
Study: 29510971

Group type: EXPERIMENTAL
Intervention: Mobile app for monitoring symptoms and patient performance during radiotherapy
Number of subjects: 50
Study: 29511004

Group type: EXPERIMENTAL
Intervention: Multimorbidity assessed with the adjusted morbidity grouper
Number of subjects: 264830

Group type: EXPERIMENTAL
Intervention: High healthcare costs to year ratio
Number of subjects: 264830
Study: 29511014

Group type: EXPERIMENTAL
Intervention: Postoperative delirium assessed using the Confusion Assessment Method on postoperative days 1, 2, 3, and day of discharge.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postoperative assessments including hospital outcomes, pain at rest, knee and hip function, health-related quality of life, and Postoperative Morbidity Survey-defined morbidity.
Number of subjects: 0
Study: 29511132

Group type: EXPERIMENTAL
Intervention: OPB-111077, 250 mg QD (maximum tolerated dose)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: OPB-111077, 250 mg QD
Number of subjects: 145
Study: 29511383

Group type: EXPERIMENTAL
Intervention: Levodopa-carbidopa intestinal gel (LCIG)
Number of subjects: 28
Study: 29511906

Group type: EXPERIMENTAL
Intervention: SCP care
Number of subjects: 395

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 395
Study: 29512061

Group type: EXPERIMENTAL
Intervention: Avelumab (immunotherapy)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Chemotherapy and radiotherapy
Number of subjects: 19
Study: 29512219

Group type: EXPERIMENTAL
Intervention: Direct-acting antiviral agents
Number of subjects: 0
Study: 29513219

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 29514175

Group type: EXPERIMENTAL
Intervention: Low isoniazid and rifampicin concentrations
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Highest quartile for area under the rifampicin and isoniazid concentration-time curves
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Rifampicin and isoniazid concentrations below the thresholds and weight <55 kg
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Low antituberculosis drug concentrations
Number of subjects: 268
Study: 29514256

Group type: EXPERIMENTAL
Intervention: Ombrabulin (15.5 mg/m2), Docetaxel (60 mg/m2), Cisplatin (75 mg/m2)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Ombrabulin (15.5 mg/m2), Docetaxel (60 mg/m2), Cisplatin (75 mg/m2) with prophylactic G-CSF
Number of subjects: 11

Group type: COMPARATOR
Intervention: Docetaxel (60 mg/m2) monotherapy
Number of subjects: 11
Study: 29514568

Group type: EXPERIMENTAL
Intervention: DPP Group Lifestyle Balance (GLB) - immediate intervention
Number of subjects: 134

Group type: COMPARATOR
Intervention: Delayed intervention (control group)
Number of subjects: 134
Study: 29514604

Group type: EXPERIMENTAL
Intervention: Serum procalcitonin (PCT) levels
Number of subjects: 124
Study: 29514611

Group type: EXPERIMENTAL
Intervention: TECNIS® ZKB00 (+2.75 D) in dominant eye and TECNIS® ZLB00 (+3.25 D) in non-dominant eye
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: TECNIS® ZKB00 (+2.75 D) and TECNIS® ZLB00 (+3.25 D)
Number of subjects: 20
Study: 29514648

Group type: EXPERIMENTAL
Intervention: Smoking (intervention group)
Number of subjects: 0
Study: 29514663

Group type: EXPERIMENTAL
Intervention: iTRAQ proteome analyses of bronchoalveolar lavage (BAL) cells from female COPD patients
Number of subjects: 43

Group type: COMPARATOR
Intervention: iTRAQ proteome analyses of bronchoalveolar lavage (BAL) cells from smokers with normal lung function
Number of subjects: 43
Study: 29514677

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) combined with Task-Oriented Balance Training (TOBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: General Health Education (GHE) combined with Task-Oriented Balance Training (TOBT)
Number of subjects: 0
Study: 29514690

Group type: EXPERIMENTAL
Intervention: Vigorous exercise group
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Moderate exercise group
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 81
Study: 29514705

Group type: EXPERIMENTAL
Intervention: Auricular acupressure on active points (AA group)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Auricular acupressure on control points (SAA group)
Number of subjects: 112
Study: 29514708

Group type: EXPERIMENTAL
Intervention: Regadenoson perfusion CMR
Number of subjects: 76
Study: 29514773

Group type: EXPERIMENTAL
Intervention: Standard care + one-way SMS reminder
Number of subjects: 300

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 300
Study: 29514815

Group type: EXPERIMENTAL
Intervention: Calgranulin-C (0.75 µg/g)
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: Calprotectin (50 µg/g)
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: Calprotectin (400 µg/g)
Number of subjects: 337
Study: 29515036

Group type: EXPERIMENTAL
Intervention: RNA analysis
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: DNA analysis
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Microbiota models (RNA and DNA)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Omeprazole treatment for 14 days
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Overall study
Number of subjects: 180
Study: 29515114

Group type: EXPERIMENTAL
Intervention: Momelotinib (MMB; JAK1/2 inhibitor)
Number of subjects: 100
Study: 29515350

Group type: EXPERIMENTAL
Intervention: Repetitive peripheral magnetic stimulation (rPMS) of the neck and back muscles followed by repetitive transcranial magnetic stimulation (rTMS) of the left prefrontal and left temporoparietal cortex, 10 sessions.
Number of subjects: 41
Study: 29515438

Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (placebo stimulation)
Number of subjects: 0
Study: 29515514

Group type: EXPERIMENTAL
Intervention: Progressive abduction loading therapy with horizontal-plane viscous resistance
Number of subjects: 32

Group type: COMPARATOR
Intervention: Progressive abduction loading therapy without horizontal-plane viscous resistance
Number of subjects: 32
Study: 29516004

Group type: EXPERIMENTAL
Intervention: Stress echocardiography
Number of subjects: 25
Study: 29517074

Group type: EXPERIMENTAL
Intervention: Higher-protein calorie-restricted diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Calorie-restricted diet
Number of subjects: 0
Study: 29517122

Group type: EXPERIMENTAL
Intervention: HR tertile 2 (77-94 b.p.m.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HR tertile 3 (>94 b.p.m.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low SBP (<119 mmHg)
Number of subjects: 0
Study: 29517567

Group type: EXPERIMENTAL
Intervention: Patient e-learning program, brief advice, educational pamphlet, tobacco quitline referral, letter to the primary care physician, and pharmacotherapy
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: Pharmacotherapy
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: Number of contacts with a tobacco quitline
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: Presence of other smokers in the household
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: Amount spent on cigarettes weekly at baseline (per $10 increase)
Number of subjects: 459
Study: 29518185

Group type: EXPERIMENTAL
Intervention: Baseline gut microbiome characterized by Proteobacteria
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Enterococcaceae dominance (relative abundance ≥30%)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Streptococcaceae dominance
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Microbial diversity after induction and reinduction phases of chemotherapy
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Relative abundance of certain bacterial taxa (Bacteroidetes)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Relative abundance of other taxa (Clostridiaceae and Streptococcaceae)
Number of subjects: 199
Study: 29518528

Group type: EXPERIMENTAL
Intervention: Intensive meditation retreat
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group of experienced meditators
Number of subjects: 0
Study: 29518553

Group type: EXPERIMENTAL
Intervention: Nivolumab (240 mg every 2 weeks) plus Crizotinib (250 mg twice daily)
Number of subjects: 13
Study: 29519282

Group type: EXPERIMENTAL
Intervention: Manual chest compression, electric defibrillation, or epinephrine ≤ 4 mg
Number of subjects: 613

Group type: EXPERIMENTAL
Intervention: In-hospital cardiac arrest (IHCA)
Number of subjects: 613

Group type: EXPERIMENTAL
Intervention: Age < 65 years, witnessed CPR, manual chest compression, electric defibrillation, or epinephrine ≤ 4 mg
Number of subjects: 613

Group type: EXPERIMENTAL
Intervention: Ambulance CA
Number of subjects: 613

Group type: EXPERIMENTAL
Intervention: Total adrenaline ≤ 4 mg
Number of subjects: 613
Study: 29519540

Group type: EXPERIMENTAL
Intervention: Hepatoportoenterostomy (successful)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Hepatoportoenterostomy (unsuccessful)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Neurodevelopmental testing using Bayley Scales of Infant Development
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Ascites
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Low length z-scores
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Low weight z-scores
Number of subjects: 148
Study: 29519776

Group type: EXPERIMENTAL
Intervention: Innovative interactive e-learning multimedia (IM) module
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional PowerPoint show (PPS) module
Number of subjects: 24
Study: 29519811

Group type: EXPERIMENTAL
Intervention: High-sensitivity troponin I (hsTnI) concentrations measured using a single-molecule counting assay (99th percentile, 6 ng/L)
Number of subjects: 991

Group type: EXPERIMENTAL
Intervention: High-sensitivity troponin I (hsTnI) concentrations
Number of subjects: 991
Study: 29519879

Group type: EXPERIMENTAL
Intervention: Treatment for retinopathy of prematurity (ROP)
Number of subjects: 6115

Group type: EXPERIMENTAL
Intervention: Screening of infants with a GA≤34 weeks or a BW<1700 g
Number of subjects: 6115

Group type: EXPERIMENTAL
Intervention: Independent risk factors for severe ROP in infants with a BW≤1500 g
Number of subjects: 6115

Group type: EXPERIMENTAL
Intervention: Overall incidence of ROP
Number of subjects: 6115

Group type: EXPERIMENTAL
Intervention: Treatment criteria
Number of subjects: 6115
Study: 29519925

Group type: EXPERIMENTAL
Intervention: Polysomnography (PSG) assessment of sleep alterations
Number of subjects: 45
Study: 29520431

Group type: EXPERIMENTAL
Intervention: Primary stenting with nitinol self-expanding stents
Number of subjects: 100

Group type: COMPARATOR
Intervention: Best medical treatment (BMT) alone
Number of subjects: 100
Study: 29520615

Group type: EXPERIMENTAL
Intervention: Diabeloop Artificial Pancreas system with customized settings and remote monitoring
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Remote monitoring by expert nurses with a web platform generating automatic Secured Information Messages (SIMs)
Number of subjects: 8
Study: 29522089

Group type: EXPERIMENTAL
Intervention: Artemisinin-based combination therapy
Number of subjects: 2399
Study: 29522186

Group type: EXPERIMENTAL
Intervention: Chronic insomnia
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cold pressor test
Number of subjects: 12

Group type: COMPARATOR
Intervention: Good-sleeper controls
Number of subjects: 12
Study: 29522222

Group type: EXPERIMENTAL
Intervention: Chronic insomnia patients
Number of subjects: 30

Group type: COMPARATOR
Intervention: Matched good sleepers
Number of subjects: 30
Study: 29522361

Group type: EXPERIMENTAL
Intervention: Bone-only metastatic breast cancer (BO MBC)
Number of subjects: 10521
Study: 29523117

Group type: EXPERIMENTAL
Intervention: Insomnia Severity Index (ISI)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Berlin Questionnaire (BQ)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Electronic medical records for insomnia
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Electronic medical records for OSA
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Characteristics associated with insomnia
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Characteristics associated with OSA
Number of subjects: 300
Study: 29523147

Group type: EXPERIMENTAL
Intervention: Alpha-linolenic acid (LNA; omega-3) intake
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Linoleic acid (LA; omega-6) intake
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA; omega-3) intake
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (DHA; omega-3) intake
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Omega-6 to omega-3 ratios
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Diet quality
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Education level in adults
Number of subjects: 352
Study: 29523153

Group type: EXPERIMENTAL
Intervention: Extracorporeal life support (ECLS) treatment
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: ECLS treatment
Number of subjects: 210
Study: 29523169

Group type: EXPERIMENTAL
Intervention: Mobile application (App My eReport France®) introduced by a neurologist to report adverse drug reactions (ADR).
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control group informed of the existence of the App but not introduced to its use, reporting ADR according to usual procedures.
Number of subjects: 180
Study: 29523171

Group type: EXPERIMENTAL
Intervention: Umbilical cord mesenchymal stem cells (UCMSC) intravenous infusions, 7 infusions of 20 × 10^6 cells each.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: UCMSC intravenous infusions
Number of subjects: 20
Study: 29523524

Group type: EXPERIMENTAL
Intervention: Chlorthalidone (thiazide-like diuretic)
Number of subjects: 310
Study: 29523908

Group type: EXPERIMENTAL
Intervention: Novel wound retractor combining continuous irrigation and barrier protection
Number of subjects: 86
Study: 29523993

Group type: EXPERIMENTAL
Intervention: mGCL in perimetric group
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: mRNFL in perimetric group
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: mGCC in perimetric group
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: mRNFL in HT perimetric group
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: pRNFL in HT perimetric group
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: mRNFL in NT groups
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: mGCL and mRNFL
Number of subjects: 212
Study: 29524090

Group type: EXPERIMENTAL
Intervention: Hypertensive group
Number of subjects: 201

Group type: COMPARATOR
Intervention: Normotensive group
Number of subjects: 201
Study: 29524759

Group type: EXPERIMENTAL
Intervention: Delayed-release dimethyl fumarate (DMF)
Number of subjects: 506